Name : BBS7 Antibody, FITC Conjugated
Supplier : BIOSS PRIMARY CONJUGATED ANTIBODIES 1
Price :333
SKU : GEN8756959516
| Long name | FITC Conjugated, BBS7 Polyclonal Antibody |
| Category | Conjugated Primary Antibodies |
| Conjugation | Anti-FITC Antibody |
| Host Organism | Rabbit (Oryctolagus cuniculus) |
| Target Antigen | BBS7 |
| Specificity | This is a highly specific antibody against BBS7 |
| Modification | Unmodified |
| Modification site | None |
| Clonality | Polyclonal |
| Clone | Polyclonal antibody |
| Concentration | 1ug per 1ul |
| Source | KLH conjugated synthetic peptide derived from human BBS7 |
| Tested applications | IF(IHC-P) |
| Recommended dilutions | IF(IHC-P)(1:50-200) |
| Crossreactivity | Mouse, Rat, Human |
| Crossreactive species details | not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Antigen background | BBS is a heterogeneous disorder mapping to eight genetic loci and encoding eight proteins, BBS patients also have an increased risk of developing diabetes, BBS1-BBS8, BBS2 contains two overlapping genes: BBS2L1 and BBS2L2, BBS7 contains 672 amino acids and is expressed at low to moderate levels in most human tissues, BBSL1 was re-named BBS7, Five BBS proteins encode basal body or cilia proteins, and congenital heart defects, and developmental delay, hypertension, hypogenitalism, photoreceptor degeneration, polydactyly, renal abnormalities, suggesting that BBS is a ciliary dysfunction disorder, whereas BBS2L2 independently funcitons as BBS1, Bardet-Biedl syndrome (BBS) is a pleiotropic genetic disorder characterized by obesity |
| Purification method | This antibody was purified via Protein A |
| Storage conditions | 50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA |
| Excitation Emission | 494nm/518nm |
| Synonyms | FLJ10715 BBS2L1 |
| Properties | Bioss Primary Conjugated Antibodies FITC is highly sensitive to pH extremes, FITC has a green emission that's usually collected at 530 nanometers, FITC has a high quantum yield (efficiency of energy transfer from absorption to emission fluorescence) and approximately half of the absorbed photons are emitted as fluorescent light, For fluorescent microscopy applications, This Bioss Primary Conjugated Antibodies Fluorescein isothiocyanate (FITC) antibody is currently after some BD antibodies the most commonly used fluorescent dye for FACS, When excited at 488 nanometers, its photo bleaching effects are not observed due to a very brief interaction at the laser intercept, the 1 FITC is seldom used as it photo bleaches rather quickly though in flow cytometry applications, the FL1 detector of a FACSCalibur or FACScan, C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24° |
| Gene target | BBS7 Conjugated |
| Short name | FITC Conjugated, BBS7 Antibody |
| Technique | Fluorescein, antibodies against human proteins, antibodies for, antibody Conjugates, Antibody |
| Label | FITC |
| Alternative name | fluorecein coupled, Bardet-Biedl syndrome 7 (Antibody to) |
| Alternative technique | antibodies |
| Alternative to gene target | BBS7 and IDBG-36452 and ENSG00000138686 and 55212, BBS7 and IDBG-639728 and ENSBTAG00000004945 and 100138953, Bbs7 and IDBG-138825 and ENSMUSG00000037325 and 71492, nuclei, protein binding, this GO :0001103 and RNA polymerase II repressing transcription factor binding and molecular function this GO :0001654 and eye development and biological process this GO :0001947 and heart looping and biological process this GO :0005515 and protein binding and molecular function this GO :0005634 and nucleus and cellular component this GO :0005737 and cytoplasm and cellular component this GO :0005813 and centrosome and cellular component this GO :0005930 and axoneme and cellular component this GO :0006357 and regulation of transcription from RNA polymerase II promoter and biological process this GO :0007224 and smoothened signaling pathway and biological process this GO :0007368 and determination of left/right symmetry and biological process this GO :0007420 and brain development and biological process this GO :0007507 and heart development and biological process this GO :0007601 and visual perception and biological process this GO :0008104 and protein localization and biological process this GO :0015031 and protein transport and biological process this GO :0032402 and melanosome transport and biological process this GO :0032436 and positive regulation of proteasomal ubiquitin-dependent protein catabolic process and biological process this GO :0034464 and BBSome and cellular component this GO :0035058 and nonmotile primary cilium assembly and biological process this GO :0036064 and ciliary basal body and cellular component this GO :0045444 and fat cell differentiation and biological process this GO :0048546 and digestive tract morphogenesis and biological process this GO :0051877 and pigment granule aggregation in cell center and biological process this GO :0060021 and palate development and biological process this GO :0060170 and ciliary membrane and cellular component this GO :0060173 and limb development and biological process this GO :0060271 and cilium morphogenesis and biological process, this GO :0001103: RNA polymerase II repressing transcription factor binding, this GO :0001103: RNA polymerase II repressing transcription factor binding and also this GO :0005515: protein binding, this GO :0005515: protein binding, Bardet-Biedl syndrome 7 |
| Identity | 18758 |
| Gene | BBS7 |
| Long gene name | Bardet-Biedl syndrome 7 |
| Locus | 4q27 |
| Discovery year | 2003-02-05 |
| GenBank acession | AF521644 |
| Entrez gene record | 55212 |
| Classification | Bardet-Biedl syndrome associated BBSome |
| Havana BLAST/BLAT | OTTHUMG00000133076 |
| Locus Specific Databases | Mutations of the Bardet-Biedl Syndrome Type 7 Gene (BBS2L1) |